Impax cleared on oxymorphone

Areverse payment made to Amneal’s Impax Laboratories by Endo to deter US generic competition to Opana ER (oxymorphone) extended-release tablets until January 2013 was not anti-competitive, US Federal Trade Commission (FTC) chief administrative law judge Mike Chappell has decided.